OneSource, a multimodal global specialty pharma CDMO launches at CPHI Milan

OneSource Specialty Pharma, a newly incorporated CDMO, formed from the merger of three CDMO businesses within the Strides Group launches at CPHI Milan. The company has a 30-year track-record of excellence in manufacturing and quality, and specializes in biologics, drug-device combinations, and soft gelatin capsules.

OneSource is strategically positioned – with the remarkable growth of GLP-1s and the BIOSECURE Act – to address the increasing demand for drug-device combinations and biologics drug substances and product. The newly combined CDMO has five world-class facilities approved by major regulatory agencies, including the US FDA, EU, and TGA, with a workforce of over 1,200 professionals. OneSource has capabilities spanning supply-constrained drug-device combinations, biologics, and soft gelatin capsules – with the capacity to produce more than 100 million injectable doses including cartridges and pre-filled-syringes and 2.4 billion soft gelatin capsules. Notably, its flagship site in Bangalore is one of the few globally capable of manufacturing both biologics drug substance and drug product on the same premises.

 OneSource’s end-to-end offering across all its platforms was established in response to its customers’ need to streamline supply chains by consolidating their outsourcing partners. The three combined businesses, each serve over 50 global clients, and together reduce complexity, cost, and resources associated with managing multiple CDMO service providers.

OneSource is projected to achieve a remarkable 32% revenue growth in 2025, with sales anticipated to reach $400 million by 2028. The company’s strong growth prospects are driven by industry trends, including the increasing self-administration of drugs via auto-injectors, led by significant success of GLP-1 medications. In addition, the BIOSECURE Act is continuing to drive significant interest as pharma partners look to increase supply chain diversity and security, and serves as a tailwind to the CDMO’s ambitious growth plans.

Neeraj Sharma, CEO of OneSource, stated, “Our vision is to blend the expertise of global CDMO giants with the agility and service levels of a challenger, all supported by our unwavering commitment to bring the most efficient and quality products to our partners. As demand for innovative CDMO solutions grows, especially for complex therapies, we are well-positioned to accelerate drug development and manufacturing for our global partners. We’re excited to participate in CPHI Milan and look forward to forging new partnerships.”

OneSource is currently undergoing regulatory approvals and, upon completion, will be listed on the India stock exchanges. Visit OneSource Pharma at CPHI Milan [stand 5C33].

About OneSource Specialty Pharma

OneSource Specialty Pharma Limited, formerly known as Stelis Biopharma Limited, is India’s first specialty pharma pure-play CDMO business. By integrating Stelis’ Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatin businesses, we are positioned to deliver exceptional services to our customers. Following the NCLT process and listing, OneSource Specialty Pharma will operate five state-of-the-art facilities in Bengaluru, India, all approved by major regulatory bodies, including the USFDA and EU authorities. Along with a team of over 1,200 professionals, including 200+ techno-commercial experts, we specialize in diverse dosage formats and advanced biologics platforms.

Our comprehensive solutions span across platforms and therapeutic modalities, including Biologics, Drug-device combinations, Complex Injectables, and Oral Technologies. Committed to innovation and excellence, we support global partners in delivering life-saving products efficiently.